Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported revenue of CA$734,028 for the second quarter ended June 30, 2026, up 43% from CA$512,756 in the same period of 2025. Revenue was broadly consistent with the CA$737,103 reported in the first quarter of 2026.
Completed U.S. patient visits increased 196% quarter over quarter to 3,911 from 1,319, while the company's active clinician network expanded from 19 to 30. Rocket Doctor said it currently has 80 providers on its roster, with the majority advancing through credentialing. In Canada, completed patient visits increased 23% year over year to 45,766 from 37,176.
"I am delighted to confirm the Company reported an organic 43% year-over-year increase in revenue for Q2 2026," Chief Executive Officer Dr. Essam Hamza stated in the company's news release. "This growth is supported by key 'in-network' payer agreements in the U.S., which have expanded our coverage to approximately 24 million covered lives across California, Maryland, and New York State."
Patient support fee revenue increased 5% from the first quarter, supported by platform utilization in Canada, while service revenue associated with the company's partnership with Rush River Research was slightly lower. The company said that revenue is expected to be recovered in the third and fourth quarters.
Rocket Doctor said certain U.S. revenues are currently recognized on a cash basis, resulting in a timing lag between patient visits and revenue recognition. The company said the full financial impact of the higher U.S. patient volume was therefore not reflected in second-quarter revenue and is expected to be recognized in future quarters.
Gross margin was 65%, compared with 75% in the first quarter of 2026 and 89% in the second quarter of 2025. The company attributed the decline to its revenue mix as it scaled its digital healthcare platform, particularly in the United States.
The company recorded a second-quarter net loss of CA$6.67 million, or CA$0.07 per share, compared with CA$4.64 million, or CA$0.05 per share, in the first quarter and CA$2.69 million, or CA$0.04 per share, a year earlier. Adjusted EBITDA was a loss of CA$4.12 million, compared with losses of CA$2.98 million in the preceding quarter and CA$1.73 million in the year-earlier period.
Cash and cash equivalents totaled CA$0.95 million as of June 30, 2026, compared with CA$0.64 million at Dec. 31, 2025.
During the quarter, Rocket Doctor expanded its U.S. insurance coverage, including agreements in Maryland and its first U.S. value-based primary care agreement. The company said its U.S. in-network footprint now covers approximately 24 million lives across California, New York, and Maryland.
Other developments included the launch of a Digital Health Observership Program with the University of Toronto for Physician Assistant students, a strategic marketing partnership with Rick Ware Racing and FINTEKK AP, and a partnership with Mindstride AI for after-hours and overflow physician coverage across Ontario, Alberta, and British Columbia. Treatment.com, the company's U.S. subsidiary, also secured US$250,000 in Year 2 NIH funding, bringing total support to more than US$500,000.
Since the end of the quarter, Rocket Doctor has announced SOC 2 Type 1 compliance, an extension of its EngageWell partnership in New York City, additional in-network access for more than 100,000 eligible members in New York, and a strategic network agreement in California. The company also closed two tranches of an oversubscribed convertible debenture financing totaling approximately CAD$3.26 million in gross proceeds.
What Could Drive Rocket Doctor's Next Stage of Growth
Rocket Doctor's August 2026 investor presentation pointed to U.S. expansion as one of the company's primary potential growth catalysts. The company reported approximately 24 million in-network patients through payer partners across California, New York, and Maryland, including 10.26 million in California, 9.98 million in New York, and 3.18 million in Maryland. Management identified Florida and Texas among the states in its expansion pipeline and said its strategy is to extend existing relationships with payers into additional markets.
Another catalyst could come from converting Rocket Doctor's physician pipeline into additional patient capacity. The presentation listed 81 physicians signed across California, New York, and Maryland, with 31 clinically active and 50 going through credentialing. Management estimated that completing this process could provide approximately three times the company's then-current physician capacity. The company said its credentialing infrastructure was developed over several years and is designed to support onboarding physicians into its U.S. payer network.
Further payer agreements represent another potential driver. Rocket Doctor's U.S. strategy targets Medicaid and Medicaid managed care, Medicare and Medicare Advantage, employer and commercial insurance plans, and out-of-network patients. Management said each additional payer relationship could provide access to 1 million to 2 million or more covered lives and create repeatable patient volume. The company also views out-of-network visits as a way to demonstrate demand to insurers and potentially convert those relationships into future payer contracts.
Streetwise Ownership Overview*
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 08/21/25 | TRUE:CSE | 1 | AIDR:CSE | 1 |
| 07/14/23 | TRUE:CSE | 10 | TRUE:CSE | 1 |
Longer term, commercialization and broader integration of Rocket Doctor's AI technology could provide additional catalysts. Its Global Library of Medicine was developed with more than 25,000 hours of clinician input and approximately 10,000 expert medical reviews, according to the presentation, and is designed for integration into telehealth, health systems, medical education, pharmacy kiosks, nurse call centers, and voice assistants. Rocket Doctor is also developing AI-assisted intake, diagnostic support, referrals, documentation, and follow-up capabilities across its care platform.
Ownership & Share Information2
Rocket Doctor AI Inc. has a market cap of approximately CA$59.61 million, with 101.04 million shares outstanding. The company's 52-week range is CA$0.50-CA$0.98.
Management & Insiders own 4.24% of shares.
Important Disclosures:
- Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
- James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026
1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
2. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
